Project description:We performed high-throughput profiling of histone modifications in mouse thymocytes in which Nsd2 were deleted (KO) or Nsd2 were substituted as following c.2717C>T; p.Pro906Leu that is an orthologous substitution of human NSD2 c.2714C>T; p.Pro905Leu (KI). We found that lysine 36 dimethylation were generally decreased in KO and KI. These were associated with regulation of gene expression.
Project description:Genome wide DNA methylation profiling of thymocytes from wild type and Nsd2 knock out (KO) and Nsd2 knock in (KI). The 906th Proline of Nsd2 was substituted to Leucine in Nsd2 KI by gene editing. The Illumina Infinium Mouse methylation Beadchip was used to obtain DNA methylation profiles across approximately 270,000 CpGs in thymocytes. Samples included 2 wild type, 2 heterozygous knock out, 1 heterozygous knock in, and 1 homozygous knock in.
Project description:We generated genome-wide H3K9me3-state maps of DP thymocytes purified from ESET+/+ and ESET-/- mice by using next generation sequencing. Examination of H3K9 trimethylation in DP thymocytes purified from ESET+/+ and ESET-/- mice.
Project description:We generated genome-wide H3K9me3-state maps of DP thymocytes purified from ESET+/+ and ESET-/- mice by using next generation sequencing.
Project description:NSD2 is a histone methyltransferase that specifically dimethylates histone H3 lysine 36 (H3K36me2), a modification associated with gene activation. Dramatic overexpression of NSD2 in t(4;14) multiple myeloma (MM) and an activating mutation of NSD2 discovered in acute lymphoblastic leukemia (ALL) are significantly associated with altered gene activation, transcription and DNA damage repair. The partner proteins through which NSD2 may influence critical cellular processes remain poorly defined. In this study, we utilized proximity-based labelling (BioID) combined with label-free quantitative mass spectrometry to identify high confidence NSD2 interacting partners in MM cells.
Project description:This SuperSeries is composed of the following subset Series: GSE29146: NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming [ChIP] GSE29147: NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming [RNAi] GSE29148: NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming [TKO] GSE29150: NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming [Transduction] Refer to individual Series
Project description:NSD2 (also named MMSET and WHSC1) is a histone lysine methyltransferase that is implicated in diverse diseases and commonly overexpressed in multiple myeloma due to a recurrent t(4;14) chromosomal translocation. However, the precise catalytic activity of NSD2 is obscure, preventing progress in understanding how this enzyme influences chromatin biology and myeloma pathogenesis. Here we show that dimethylation of histone H3 at lysine 36 (H3K36me2) is the principal chromatin-regulatory activity of NSD2. Catalysis of H3K36me2 by NSD2 is sufficient for gene activation. In t(4;14)-positive myeloma cells, the normal genome-wide and gene-specific distribution of H3K36me2 is obliterated, creating a chromatin landscape that selects for a transcription profile favorable for myelomagenesis. Catalytically active NSD2 confers xenograft tumor formation and invasion capacity upon t(4;14)-negative cells and NSD2 promotes oncogenic transformation of primary cells in an H3K36me2-dependent manner. Together our findings establish H3K36me2 as the primary product generated by NSD2, and demonstrate that genomic disorganization of this canonical chromatin mark initiates oncogenic programming. Genome-wide expression profiling of KMS11 cells stably transduced with control vector in comparison to two independent shRNAs against NSD2. Each cell line is tested in duplicate.